Ex vivo and preclinical assessment of an endothelial progenitor cell capturing bioengineered stent

Minerva Cardioangiologica

Volumn 60, Issue 1, 2012, Pages 11-21

  Yazdani, S K ^a   Kolodgie, F D ^a   Virmani, R ^a  

^a CVPATH INSTITUTE   (United States)

Author keywords

Endothelial cells; Stents; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIBODY; EVEROLIMUS; RAPAMYCIN;

ANGIOCARDIOGRAPHY; BARE METAL STENT; BIOENGINEERING; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; EX VIVO STUDY; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENICITY;

ANIMALS; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; PROSTHESIS DESIGN; STENTS; TISSUE ENGINEERING;

EID: 84858851394     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95. (Pubitemid 24256751)
2. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95. (Pubitemid 32433720)
3. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93. (Pubitemid 32830406)
4. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. (Pubitemid 38067635)
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. (Pubitemid 37186209)
7. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. (Pubitemid 34586912)
8. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78. (Pubitemid 46281313)
9. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. (Pubitemid 43929240)
10. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10. (Pubitemid 46986103)
11. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41. (Pubitemid 46717966)
12. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21. (Pubitemid 39410418)
13. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9. (Pubitemid 40342825)
14. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005;111:1619-26. (Pubitemid 40525161)
15. Balakrishnan B, Dooley J, Kopia G, Edelman ER. Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release 2008;131:173-80.
16. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. (Pubitemid 29035956)
17. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994;24:1398-405. (Pubitemid 24331884)
18. Haudenschild CC, Schwartz SM. Endothelial regeneration. II. Restitution of endothelial continuity. Lab Invest 1979;41:407-18. (Pubitemid 10164032)
19. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8. (Pubitemid 29377293)
20. De Val S. Key transcriptional regulators of early vascular development. Arterioscler Thromb Vasc Biol 2011;31:1469-75.
21. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000;87:728-30.
22. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004;44:733-9. (Pubitemid 39099565)
23. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-9. (Pubitemid 40704488)
24. Duckers HJ, Soullie T, den Heijer P, Rensing B, de Winter RJ, Rau M et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). Eurointervention 2007;3:350-8.
25. den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W et al. Final results of the HEALING HB trial to evaluate a bio-engineered CD34 antibody coated stent (GenousStent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Atherosclerosis 2011;2011:25.
26. Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE et al. Clinical results after coronary stenting with the Genous Bio-engineered R stent: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Eurointervention 2011;6:819-25.
27. Duckers HJ, Silber S, de Winter R, den Heijer P, Rensing B, Rau M et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 2007;3:67-75.
28. Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H et al. Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genous bio-engineered R stent in patients from the e-HEALING registry. Catheter Cardiovasc Interv 2011;2011:23156.
29. Kutryk M, Kuliszewski M. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am J Cardiol 2003,92:94L.
30. Larsen K, Cheng C, Tempel D, Parker S, Yazdani S, den Dekker WK et al. Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model. Eur Heart J 2011;2011:6.
31. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 2010;3:257-66.
32. Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010;3:68-75.
33. Plouffe BD, Kniazeva T, Mayer JE Jr, Murthy SK, Sales VL. Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. Faseb J 2009;23:3309-14.
34. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8. (Pubitemid 30062717)
35. Martin-Yuste V, Brugaletta S, Ferreira-Gonzalez I, Cola C, Alvarez-Contreras L, de Antonio M et al. Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. Eurointervention 2011;6:831-7.